Sveinn Sölvason, President and CEO, comments:

“Sales in Q3 2026 were USD 250 million, representing 5% reported growth and 4% organic growth. Growth was driven by Prosthetics & Neuro Orthotics, with strong performance in EMEA, partially offset by softer results in Americas and APAC. Bracing & Supports delivered moderate growth, while Patient Care sales were flat in the quarter.

In Patient Care, sales performance has been below the expectations we set at the beginning of the year. Mainly as significant integration effort has slowed down our ability to drive growth in patient volumes in selected regions. We are encouraged by the progress we are making in a large part of our network of clinics, with significant work ongoing to enhance our performance across the whole Patient Care network.

EBITDA margin was strong in the quarter, or 22%, in line with Q3 2025, as disciplined cost control offset lower gross profit margin.

Based on our performance in the first nine months and our outlook for Q4 2026, we are narrowing our full-year guidance to approximately 5% organic sales growth (previously 5–7%) and an EBITDA margin of approximately 21% (previously 20–22%).”

A webcast can be viewed by selecting the link below:
Embla Medical Q3 2026 Webcast⁠ (Transcript)⁠

Related documents:

• Company Announcement⁠ (PDF)
• Investor Presentation⁠ (PDF)